Adalimumab
Dosage form: Subcutaneous injection by Autoinjector, Pre-Filled Syringe, Single-Dose Vial
Usage of Adalimumab
Adalimumab is the generic name for the medicine Humira and the biosimilars of Humira. Adalimumab is a TNF alfa inhibitor used to reduce pain, inflammation, and skin symptoms in chronic autoimmune conditions. Adalimumab is used to treat certain types of rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (Ps), Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, ankylosing spondylitis, and uveitis. Adalimumab works by reducing a substance in the body that can cause inflammation.
Adalimumab is a biologic medication that is a fully human monoclonal antibody, which targets tumor necrosis factor alpha (TNFa).
There are 9 biosimilars of Humira, the brand names are Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, and Yusimry. The interchangeable biosimilars of Humira are Cyltezo (Boehringer Ingelheim) and Abrilada (Pfizer).
Humira was approved by the FDA on December 31, 2002. Humira was the first brand of adalimumab, so it is called the reference product. Biosimilars of Humira are now also available, see below for a full list of adalimumab biosimilars, indications, and companies.
A biosimilar is a biologic medicine that is a very close copy of the original product made by another company. An interchangeable biosimilar has undergone an additional Interchangeability Study, meaning that patients can be confident in the safety and effectiveness of the interchangeable biosimilar product, just as they would be for the FDA-approved original product, in this case, Humira.
Adalimumab side effects
Common adalimumab side effects of may include:
Serious adalimumab side effects of may include:
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor right away if you have any symptoms of lymphoma:
Also call your doctor at once if you have:
Older adults may be more likely to develop infections or cancer while using adalimumab.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Adalimumab
Before you start using adalimumab, tell your doctor if you have signs of infection - fever, chills, sweats, muscle aches, tiredness, cough, bloody mucus, skin sores, diarrhea, burning when you urinate, or feeling constantly tired.
Adalimumab should only be given to children if the brand is indicated for their condition and age group. Children using adalimumab should be current on all childhood immunizations before starting treatment.
Tell your doctor if you have ever had:
Tell your doctor where you live and if you have recently traveled or plan to travel. You may be exposed to infections that are common to certain areas of the world.
Adalimumab may cause a rare type of lymphoma (cancer) of the liver, spleen, and bone marrow that can be fatal. This has occurred mainly in teenagers and young men with Crohn's disease or ulcerative colitis. However, anyone with an inflammatory autoimmune disorder may have a higher risk of lymphoma. Talk with your doctor about your own risk.
Pregnancy
It is not known whether adalimumab will harm an unborn baby. Tell your doctor if you are pregnant or planning a pregnancy. Make sure any doctor caring for your newborn baby knows if you used adalimumab while you were pregnant, and especially before your baby receives any vaccines.
Breastfeeding
It may not be safe to breastfeed a baby while you are using adalimumab. Ask your doctor about any risks and the best way to feed your baby while on this medicine.
How to use Adalimumab
Different brands of adalimumab are available in different dosage forms and strengths, these are the approved forms and strengths for each brand.
Humira is available as:
Abrilada is available as:
Amjevita is available as:
Cyltezo is available as:
Hadlima is available as:
Hulio is available as:
Hyrimoz is available as:
Idacio is available as:
Yuflyma is available as:
Yusimry is available as:
The dose and frequency of adalimumab given is dependent on age, severity, and condition treated. For more information on specific dosing schedules click the link below.
Warnings
Adalimumab affects your immune system. You may get infections more easily, even serious or fatal infections.
Before or during treatment with adalimumab, tell your doctor if you have signs of infection such as fever, chills, aches, tiredness, cough, skin sores, diarrhea, or burning when you urinate.
Your doctor should test you for tuberculosis (TB) before you start taking adalimumab and also monitor you closely for signs and symptoms of TB during treatment.
The chances of getting cancer may be increased for children and adults taking TNF-blockers.
What other drugs will affect Adalimumab
Some drugs should not be used together with adalimumab. Tell your doctor about all medicines you use, and those you start or stop using during your treatment with adalimumab, especially:
This list is not complete. Other drugs may interact with adalimumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Popular FAQ
You can take Humira with an antibiotic if your doctor has prescribed both of these medications for you. There may be some antibiotics that are not safe to take with Humira, so do not start taking any antibiotic without prior approval from your doctor. Continue reading
Amjevita is not yet interchangeable with Humira, and the pharmacist must get approval from your doctor before they can substitute it for Humira. To date, the only approved interchangeable biosimilar for Humira is Cyltezo, which was granted this status by the FDA in October 2021. Cyltezo will be commercially available July 1, 2023. Continue reading
Both Cosentyx and Humira are subcutaneous injections (which means given under the skin) that may be used to treat certain inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. After an initial loading dose, Humira is given every two weeks and Cosentyx every four weeks. Continue reading
In a head-to-head clinical study between Skyrizi and Humira, researchers found that Skyrizi was better than Humira at clearing moderate-to-severe plaque psoriasis in adults. At 16 weeks, 72% of patients given Skyrizi achieved 90% clearer skin compared to 47% of patients given Humira, a statistically significant outcome. Continue reading
You can take Humira with an antibiotic if your doctor has prescribed both of these medications for you. There may be some antibiotics that are not safe to take with Humira, so do not start taking any antibiotic without prior approval from your doctor. Continue reading
Both Cosentyx and Humira are available as subcutaneous injections (which means given under the skin) and may be used to treat certain inflammatory conditions such as plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and ankylosing spondylitis. Cosentyx is also available as an IV injection that can be administered by a healthcare provider. After an initial loading dose, Humira is given every two weeks and Cosentyx every four weeks. Continue reading
Amjevita is not yet interchangeable with Humira, and the pharmacist must get approval from your doctor before they can substitute it for Humira. To date, the only approved interchangeable biosimilar for Humira is Cyltezo, which was granted this status by the FDA in October 2021. Cyltezo will be commercially available July 1, 2023. Continue reading
In a head-to-head clinical study between Skyrizi and Humira, researchers found that Skyrizi was better than Humira at clearing moderate-to-severe plaque psoriasis in adults. At 16 weeks, 72% of patients given Skyrizi achieved 90% clearer skin compared to 47% of patients given Humira, a statistically significant outcome. Continue reading
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions